NIH has charted the Application Review Process to be followed during the COVID-19 pandemic. The chart covers flexibilities provided for the current and next round of peer review.

(UPDATED 11/4/20) NIH will not consider contingency plans regarding the COVID-19 pandemic in applications for funding (NOT-OD-21-026). Contingency plans will not be considered during the peer review process. 

(UPDATED 11/5/20) NIH may not require use of single IRB for research with an approved exception. These exceptions represent an effort to prioritize the health and safety of both research subjects and investigators, and provides flexibility to institutions in seeking IRB review due to the unique challenges created by the COVID-19 outbreak. Please see NOT-OD-21-006 for details on NIH supported studies.

(UPDATED 9/30/20) NIH, AHRQ, AND NIOSH continues extension of  exception to the policy for post-submission materials (NOT-OD-20-179 and NOT-OD-20-163 and NOT-OD-20-123) for applications submitted for the August/October 2021 Council. A one-page update with preliminary data will be accepted as post-submission materials, ONLY if the FOA used for submission of the application allowed preliminary data in the application.

(UPDATED 8/17/2020) NIH will be providing up to a two-receipt cycle extension (roughly eight additional months) of eligibility for prospective K99/R00 applicants who have/will reach the 4 year eligibility threshold while experiencing delays in application submission due to disruptions caused by the COVID-19 pandemic. The extension will apply only to eligible applicants submitting new and resubmission K99/R00 applications under parent announcements PA-20-187, PA-20-188, and PA-20-189, which will be automatically accepted by NIH. This extension is temporary and subject to change. K99 applicants who wish to receive non-COVID-related extensions, (e.g. for childbirth, adoption, family leave, etc.) must continue to provide relevant documentation.

Note: ICs are issuing Change Notices for specific FOAs announcing Changes to Key Dates, please check new Change Notices for extensions and date revisions in the NIH weekly Guide or by checking the browser version of the FOA for Related Notices.

SOURCE: NIH GPS 2.3.9, NIH FAQs, NOT-OD-20-082, NIH COVID-19 Q&A recording, NOT-OD-20-091, NOT-OD-20-105, NOT-OD-20-123, NOT-OD-20-158, NOT-OD-20-163, NOT-OD-21-026, NOT-OD-21-006 

NSF has extended deadline dates for specific funding opportunities listed on the Foundation’s COVID-19 webpage. Deadline for funding opportunities that do not appear on the list remain unchanged. If unable to meet stated NSF deadlines please contact the cognizant NSF Program officer to discuss the issue ideally BEFORE the deadline. NSF will consider extension on a case-by-case basis.  Principal Investigators should work with their RSC to follow guidance given by NSF Program Officer for submitting late application. NSF website has a list of impact on existing deadline dates.   

SOURCE: NSF COVID-19 FAQs, PAPPG Chapter 1.F , NSF Implementation of OMB M-20-17

DOD recommends that program offices provide flexibility with upcoming proposal deadlines to the extent allowable by funding authorities and by the time needed for merit review of submitted proposals. Please contact the program officer and grants manager for the funding opportunity in question to request an application deadline extension. Proposers are encouraged to monitor grants.gov to see if an extension has been posted.

SOURCE: FAQs for DOD Research Proposers and Awardees Impacted by COVID-19

There are currently no plans to modify existing deadline dates. Applicants should monitor Grants.gov for any potential changes to an application deadline.

The unique and evolving circumstances related to COVID-19 create multiple challenges for conducting reviews that limit the extent to which timelines for funding can be delayed. Current funding opportunity announcement deadlines allow as much time as possible for application submissions, and further modification of application deadlines is not anticipated.

• Contact CDMRP Helpdesk at [email protected] or 301-682-5507 for further assistance.
• Please check the USAMRAA COVID-19  webpage periodically for future updates.

SOURCE: USAMRAA’s COVID-19, USAMRAA Supplemental Guidance April 30, 2020

CDC will consider extending the application due date beyond the date specified in the Notice of Funding Opportunity (NOFO) on a case-by case basis.  Principal Investigators should work with their RSC to submit your request to extend the NOFO deadline to the assigned grants management specialist/program official noted in the Notice of Funding Opportunity under Agency Contacts prior to the NOFO closing date. The request should include enough detail about the delay so that CDC can determine whether circumstances justify extending the NOFO application submission deadline. 

SOURCE: Flexibilities Available to Applicants and Recipients Affected by COVID-19 and FAQs

No guidance at this time

ACFwill post specific guidance on its websites and/or provide a point of contact for an Agency program official.

SOURCE: Administration for Children & Family IM-ACF-OA-2020-01

(UPDATED 11/5/20) AHRQ may not require use of single IRB for AHRQ-funded research with an approved exception. These exceptions represent an effort to prioritize the health and safety of both research subjects and investigators, and provides flexibility to institutions in seeking IRB review due to the unique challenges created by the COVID-19 outbreak. Please see NOT-OD-21-002 for details on AHRQ-supported studies.

SOURCE:  NOT-HS-20-010, NOT-HS-21-002

No guidance at this time.

Pre-award costs may be incurred (at your own risk) up to 90 calendar days prior to the start date of the initial budget period as long as costs are necessary conduct the project and would be allowable, if awarded, without NIH prior approval.

SOURCE: NIH FAQs, NOT-OD-20-086, NIH Grants Policy Statement, Ch. 7, Exhibit 5

Pre-award costs may be incurred (at your own risk) up to 90 calendar days prior to the start date of the period of performance, as long as costs are made and document in accordance with the recipients’ procedures and is necessary for the effective and economical conduct of the project. Prior Approval required for pre-award costs for periods exceeding 90 days.

SOURCE: NSF PAPPG Chapter X.A.2.b

Pre-award costs may be incurred (at your own risk) up to 90 calendar days prior to the start date of the period of performance, as long as costs are allowable charges to the project or program.

SOURCE: DOD Research & Development (R&D) General Terms and Conditions, Part 2, Article V., Section C, Financial and Program Management

Pre-award costs may be incurred (at your own risk) up to 90 calendar days prior to the start date of the period of performance, as long as costs are allowable charges to the project or program. Defers to ( DoD Research & Development (R&D) General Terms and Conditions, Part 2, Article V., Section C, Financial and Program Management.

Recipients should consult the Grant Officer regarding other potential prior approval waivers based on project-specific circumstances.

All costs charged to Federal awards must be consistent with Federal cost policy guidelines and the terms of the award, except where specified in OMB Memorandum M-20-17 - expired June 16, 2020

USAMRAA will extend flexibilities to awards that support efforts related to COVID-19 on a case-by-case basis. Please work with your OSR Staff to contact the Grants Management Specialist or Grants Officer’s Representative listed in the award document for information concerning individual awards.

SOURCE: USAMRAA Supplemental Guidance March 25, 2020, FAQs from COGR March 19, 2020

No guidance at this time

No guidance at this time

No guidance at this time

No guidance at this time. 

SOURCE: NOT-HS-20-010

No guidance at this time.

NIH

Under the Standard Terms of award, recipients of SNAP awards can carryover an unobligated balance to a subsequent budget period. Recipients of non-SNAP awards have the discretion to carry forward unobligated balances on their active award for immediate efforts to support activities related to or affected by COVID-19 as long as the charges are allowable costs and are within the scope of the original award.

SOURCE: NIH GPS 8.1.1.2, NIH FAQs, NOT-OD-20-086, NOT-OD-20-087

NSF

No guidance at this time

DOD

Carry forward of an unobligated balance to a subsequent period of performance under the award is allowed.

SOURCE: DOD Research & Development (R&D) General Terms and Conditions, Part 2, Article V., Section C, Financial and Program Management

DOD-USAMRAA

Allows carry forward of an unobligated balance to a subsequent period of performance under the award. Defers to the DoD Research & Development (R&D) General Terms and Conditions, Part 2, Article V., Section C, Financial and Program Management.

Recipients should consult the Grant Officer regarding other potential prior approval waivers based on project-specific circumstances.

All costs charged to Federal awards must be consistent with Federal cost policy guidelines and the terms of the award, except where specified in OMB Memorandum M-20-17 - expired June 16, 2020

USAMRAA will extend flexibilities to awards that support efforts related to COVID-19 on a case-by-case basis. Please work with your OSR Staff to contact the Grants Management Specialist or Grants Officer’s Representative listed in the award document for information concerning individual awards.

SOURCE: USAMRAA Supplemental Guidance March 25, 2020, FAQs from COGR March 19, 2020

CDC

No guidance at this time

HHS-OSHA*

No guidance at this time

ACF

No Guidance at this time

AHRQ

No guidance at this time

SAMHSA

SAMHSA is currently reviewing requests to carryover unspent funds from discretionary grant recipients that submitted carryover requests at the end of their last budget period. Recipients should wait to receive a response to their carryover request before submitting a new request to reallocate carryover funding. Recipients should notify their GMS of their intent to modify their carryover request.

SOURCE: COVID-19 Information for SAMHSA Discretionary Grant Recipients

Under the Standard Terms of award, recipients may extend the final year of the approved project period of an active grant up to 12 months. Affected recipients that have active non-SNAP awards may extend the final budget period of the approved project period of an active grant up to 12 months, without prior approval, by working with their RSC to notify the assigned grants management specialist.

To support participant health and safety, and continuity of research during this public health emergency, NIH will allow for additional extensions, including mid-project period extensions, for awards supporting NIH-funded clinical trials and human subjects research.

NIH will allow awards supporting clinical trials and other human subjects research to extend beyond the typical 7-year timeframe for extensions related to COVID-19.

SOURCE: NIH GPS 8.1.1.3, NIH FAQs, NOT-OD-20-086, NOT-OD-20-087

All NSF grants are eligible for a one-year recipient approved no-cost extension and then further extensions as approved by NSF. If you foresee a need for NSF-approved extensions, you should include that information in your annual report and discuss the need ahead of time with the cognizant NSF program officer for your award.

SOURCE: NSF COVID-19 FAQs and  (PAPPG), Chapter VI.D.3

It is DOD policy that no-cost extensions be supported in all possible cases; however, be please be aware that funding expiration statutes may prohibit extensions. Please contact the DOD grants manager for award-specific guidance.

SOURCE: FAQs for DOD Research Proposers and Awardees Impacted by COVID-19

Recipients have the authority to extend the period of performance one-time up to 12 months beyond the original completion date stated in the award by working with your OSR Staff to notifying the Grant Officer once you have assessed how much additional time will be needed.

Recipients of multiple awards should work with their OSR Staff to notify Grants Officer of multiple awards that need an extension. Applicable grant numbers should be included in the notification.

Additional time beyond the initial 12 months requires prior approval. 

Please be aware that funding expiration status may prohibit extensions - recipients should contact the Grants Officer for award-specific guidance.

USAMRAA will extend flexibilities to awards that support efforts related to COVID-19 on a case-by-case basis. Please work with your OSR Staff to contact the Grants Management Specialist or Grants Officer’s Representative listed in the award document for information concerning individual awards.

SOURCE: USAMRAA Supplemental Guidance March 25, 2020, FAQs from COGR March 19, 2020

• Requests must come from the institution’s business officer addressed to the Program Officer (using appropriate email), Grant Officer, and [email protected].
• A grant modification will be issued by the Grant Officer.
• The no-cost extension is not official until it is signed by the Grant Officer.
• Awards expiring after December 31, 2020 that require a no-cost extension will be examined when the need arises.

SOURCE:  AFOSR Memorandum to Grantees 26Mar2020

Due to the impact of COVID-19, CDC may extend awards that were active as of March 31, 2020, and scheduled to expire prior or up to December 31, 2020, automatically at no cost for a period of up to 12 months. No-cost extensions will be considered on a case-by-case basis. When CDC provides no-cost extensions, this will allow time for recipient assessments, the resumption of many individual projects, and a report on program progress and financial status to agency staff. Project-specific financial and performance reports will be due 90 days following the end date of the extension. CDC will examine the need to extend other project reporting as the need arises. Recipients should work with  their RSC to reach out to their assigned grants management specialist/program official if they anticipate needing a no-cost extension.

SOURCE: Flexibilities Available to Applicants and Recipients Affected by COVID-19

No guidance at this time

Flexibilities are applicable to ACF applicants and recipients where the entity is conducting human service activities related to or affected by COVID-19. Affected entities are those that have been closed or that have business activities that are hindered due to COVID-19 precautionary measures and/or illnesses. Affected entities will be asked to provide documentation to the respective ACF Program Office describing the effects, including how long the program and ACF-related work or instruction were and/or will be affected.

If permitted by law  and at the discretion of appropriate Program Office, ACF will consider no-cost extension requests for awards active as of March 31, 2020 and scheduled to expire up to December 31, 2020, for a period up to 12 months, to allow time for recipient assessment, project resumption, and a report on program progress and financial status to ACF.

SOURCE: Administration for Children & Family IM-ACF-OA-2020-01

Recipients of awards made under expanded authorities are allowed a one-time no-cost extension of the final year, up to 12 months and should notify AHRQ if this allowance is exercised. Recipients of awards not made under expanded authorities should request prior approval for a no-cost extension of the final year. Please work with your OSR Staff to execute either action as required by the award.

SOURCE: NOT-HS-20-010

SAMHSA understands that discretionary grant recipients are limited in their grant activities because of COVID-19. In these cases recipients should notify their GMS and GPO of their intent to submit a NCE. NCE forms are posted on the SAMHSA site.

SOURCE: COVID-19 Information for SAMHSA Discretionary Grant Recipients

OMB Memo M-20-17 (expired) allowed recipients to charge NIH awards for costs directly related to the affected grant project. OMB Memo M-20-26 (expired) extended the flexibility to charge salaries and benefits to active Federal awards during the period from June 18 to September 30, 2020, with additional caveats.

As of October 1, 2020, salaries and related benefits should not be charged to federal awards for individuals who are unable to perform any work on those awards.

All leave benefits remain allowable and should continue to be charged unless exhausted including vacation and COVID Paid Administrative Leave, etc.  Outside of those leaves, any effort that is not benefitting the federal award must be redirected to another funding source effective October 1, 2020. 

The Office of Sponsored Research and Contracts and Grants Accounting will update the campus if any additional guidance is provided by OMB, or particular sponsors (e.g. NIH). If you have any questions or concerns, please contact Winona Ward or Ellyn McCaffrey.

SOURCE: https://controller.ucsf.edu/news/202010/contracts-grants-accounting/update-federal-grant-flexibilities-provided-m-20-17-m-20-26

Salary supplementation for NRSA stipends is not a cost supported by an NIH project, and is not allowable. NIH remains committed to supporting and providing maximum flexibilities to its recipients; however, in doing so, NIH must remove options that would pose audit risks for unallowable charges.

Clarification: Stipends and other expenses may not be charged to NRSA awards for trainees and fellows who have not yet been appointed and cannot travel to the U.S. to start work on their NIH-funded projects.

Clarification: Recipients may not initiate charges for salaries and benefits on new awards where the work has not yet started. Recipients may only charge salaries and benefits when no work is performed on currently active awards, when their organization’s current policy allows for the charging of salaries and benefits to currently active awards (under unexpected or extraordinary circumstances) from all funding sources, Federal and non-Federal.

If the recipient’s performance site/facilities are open and/or telework options are available for work to begin, recipients may charge salaries and benefits to NIH grant awards.

Recipient institutions should consult with their Human Resources Department to determine whether there are internal policies in place allowing employees to take paid leave, and to charge the grant, regardless of the source of funds, e.g. emergency or disruptive event policies. 

As a result of COVID-19, recipients conducting NIH-funded clinical trials and human subject studies may incur unanticipated costs (e.g. Costs incurred to arrange for participants to receive care at their local sites or virtually). Recipients should notify the funding IC of any changes necessary to maintain the health and safety of participants and staff. 

While NIH ICs plan (based on availability of funds) to issue administrative supplements when absolutely necessary. COVID-19 related administrative supplement requests should be submitted:

• When the full impacts of the pandemic on the recipient's NIH supported research are clear
• When the recipient has had a chance to discuss the various options with relevant NIH staff and it was agreed that an administrative supplement is the best option for the project.

Exceptions to the above recommendations:

• Supplements to existing projects that will allow investigators to immediately address scientific questions of direct relevance to the COVID-19 epidemic
• Supplements that are needed to address immediate mission critical needs over the next 3 months.

Researchers that meet these exceptions should work with their OSR Staff to raise these issues with their program officers and/or grants management specialist prior to submitting requests.

Recipients should not assume the NIH ICs will provide additional funds to replace the donated PPE and supplies. Funding ICs should be consulted for specific details regarding supplemental support.

If project staff is required to perform their originally approved work remotely from a foreign country due to COVID-19 travel restrictions, where no grant funds are going to a foreign entity, NIH has determined that this scenario does not fit the definition of a foreign component as outlined in the NIH Grants Policy Statement  (i.e. the performance of a significant scientific element or segment of the project outside of the US.

SOURCE: NIH FAQs, NOT-OD-20-086, NOT-OD-20-087, COGR OUTREACH, OMB M-20-17, OMB M-20-18, NOT-CA-20-082, PA-18-591, PA-20-272 

OMB Memo M-20-17 (expired) allowed recipients to charge NIH awards for costs directly related to the affected grant project. OMB Memo M-20-26 (expired) extended the flexibility to charge salaries and benefits to active Federal awards during the period from June 18 to September 30, 2020, with additional caveats.

As of October 1, 2020, salaries and related benefits should not be charged to federal awards for individuals who are unable to perform any work on those awards.

All leave benefits remain allowable and should continue to be charged unless exhausted including vacation and COVID Paid Administrative Leave, etc.  Outside of those leaves, any effort that is not benefitting the federal award must be redirected to another funding source effective October 1, 2020. 

The Office of Sponsored Research and Contracts and Grants Accounting will update the campus if any additional guidance is provided by OMB, or particular sponsors (e.g. NIH). If you have any questions or concerns, please contact Winona Ward or Ellyn McCaffrey.

SOURCE: https://controller.ucsf.edu/news/202010/contracts-grants-accounting/update-federal-grant-flexibilities-provided-m-20-17-m-20-26

NSF will evaluate the grantee’s ability to resume project activity in the future and appropriateness of future funding, based on subsequent project reports and other communications with the recipient. 

Payroll costs paid with the Paycheck Protection Program (PPP) loans or any other Federal Coronavirus Aid, Relief, and Economic Security (CARES) Act programs must not be charged to current NSF awards.

Recipients are reminded of their responsibility to maintain appropriate records and cost documentation  to substantiate any salaries and other project costs related to interruption of operations or services as required by 2 CFR 200.302 and 2 CFR 200.333.

SOURCE: NSF Implementation of OMB M-20-17, OMB M-20-17, NSF Implementation of OMB M-20-26, OMB M-20-26 

In general recipients may rebudget funds to other activities because of the current situation, as long as the activities are allowable under the FOA and in line with the statutory requirements of the award. Recipients should contact their GPO and GMS about any such repurposing of funds.

Grant recipients have flexibility to rebudget (25% of the current budget or $250,000 whichever is less) as long as rebudgeting includes activities that are allowable under the FOA, within the scope of the grant, and in line with the statutory requirement of the award. Recipients must keep documentation of all costs and SAMHSA may request this documentation during the grant period.

If the amount to be rebudgeted is greater than 25% of the current budget or $250,000 whichever is less, the recipient MUST submit a COVID-19 post award amendment through the eRA Commons (see sample revised budget to be used).

Recipients may switch from planned face-to-face service/training/meetings to conducting these activities virtually. If budget modifications are needed to do this, recipients should submit a revision request.

SAMHSA grant funds can be used to purchase Personal Protective Equipment (PPE) for authorized grant personnel working in service of the grant. SAMHSA grant funds cannot be used to purchase PPE for unrelated grant activities.

SAMHSA grant funds can be used to purchase laptops and other devices to deliver training and services specified under the grant, including the purchase of software to facilitate the delivery of services and training. SAMHSA grant funds cannot be used to purchase laptops and other devices for personal use or for clients. In addition, the purchasing of internet services for clients is not authorized.

SOURCE: COVID-19 Information for SAMHSA Discretionary Grant Recipients

• Recipients must report on the effects of COVID-19 on the NIH funded research in their next RPPR submission. Recipients are not to submit standard letters, these details must be submitted within the RPPR. The funding IC will consider the effects that are reported by the recipient when reviewing and approving the RPPR. 
• Recipients of NIH-funded clinical trials and human subject studies affected by COVID-19 should consult UCSF Directives to Clinical and Non-Laboratory Researchers about potential measures to protect participants and staff.
• If UCSF facilities are closed due to COVID-19  and research labs and results cannot be maintained due to the closure. Before submitting requests for administrative supplements: the full impacts of the pandemic on the NIH-supported research should be clear and recipients have worked with their OSR Staff  to contact relevant NIH staff to discuss various options and agreed that an administrative supplement isthe best option for the project.
• If a delay in research progress is anticipated recipients may extend the final budget period of the approved project period on active grants one time for up to 12 months without seeking prior approval from the NIH (see no-cost extension).
• CLOSEOUT REPORTS: If it is anticipated that there will be a delay in the submission of closeout reports (e.g. financial, performance, inventions, and other reports per the terms of award for the closeout of expired awards) due to the effects of COVID-19, under the standard terms of award, recipients may extend the final year of the project period up to 12 months (see No-Cost Extension). If award does not allow a no-cost extension and additional time is needed, work with your OSR Staff to notify the funding IC and the NIH Closeout Center at [email protected] and provide a detailed justification on the effects of COVID-19 on the institution and grants where reporting will be delayed. Such delays may not exceed one year.
• Recipients of NIH awards for supplemental funding from the Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 (PL 116-123), are not required to submit an RPPR for these activities, special reporting requirements will be included in the terms and conditions of the award for all awards issued using COVID-19 funds.  COVID-19 funds will be issued in separate subaccounts in the HHS Payment Management System, with a 'CV' suffix. In order to track these special appropriations, recipients will be required to submit separate Federal Financial Reports (FFRs) for these subaccounts.
• COVID-related flexibilities for updating and correcting study information in ClinicalTrials.gov: though important to ensure accurate and up-to-date clinical trial information is available to the public on ClinicalTrials.gov, particularly for COVID-19 related research, NIH acknowledges that delayed updates and corrections may be unavoidable due to the impact of the public health emergency on research-related staff. Refer to Top Questions from Responsible Parties Related to COVID-19 for information on specific questions.
• Foreign Postdoctoral Fellows on NIH-funded studies: if a foreign postdoctoral fellow is working in the U.S. on a NIH funded study and needs to return to his/her home country and will continue to work remotely on the study, this would qualify as a foreign component. If this is a consideration, please work with your OSR Staff to obtain prior approval to add a foreign component to the award and report as such on the RPPR.
• Delays to phased Career Development awards, research training awards, and fellowships:
• Phased awards (e.g. K22 or K99/R00) career development, research training awards and individual fellowships, that experience delays are allowed extensions by notifying the funding IC. Please work with your OSR Staff to prepare and submit such communications to the funding IC.

• Recipients of phased Career Development awards (e.g. K99/R00) who are unable to transition to faculty position due to delays caused by COVID-19 should with their mentors contact the funding IC in writing to provide details of the delays. Please work with your OSR Staff to prepare and submit communications to the funding IC.

• Due to the varying needs of T35 recipients, NIH will handle flexibilities for these awards on a case-by-basis. Please work with your OSR Staff to submit your request to the funding IC.
• T32/T35 recipients may be able to carryover unused funds from the prior budget period. Please work with your OSR Staff to notify the funding IC.

SOURCE: NIH FAQs, NOT-OD-20-086, NOT-OD-20-087

USAMRAA will extend flexibilities to awards that support efforts related to COVID-19 on a case-by-case basis. Please work with your OSR Staff to contact the Grants Management Specialist or Grants Officer’s Representative listed in the award document for information concerning individual awards.

If the effects of COVID-19 impact the conduct of a DoD-supported human subjects research protocol, recipient should seek local guidance from their IRB and notify the USAMRAA Human Research Protection Office (HRPO) in the following circumstances:

• Substantive amendments require HRPO review and approval prior to implementation. HRPO will not require pre-approval of amendments intended to minimize the risk of COVID-19 exposure for study participants or study team members; follow local IRB review and approval and forward documents to HRPO via email at: [email protected]
• Unanticipated problems involving risks to subjects and others, which include inadvertent exposure of research subjects or study personnel to COVID-19, missed or delayed safety assessments due to pandemic, inability to provide study product or conduct key research interventions. These should be promptly reported to the reviewing IRB and to HRPO via email at: [email protected]
• Promptly report any actions taken to halt the conduct of ongoing human subjects research (e.g. pausing new enrollment, canceling follow-up procedures for previously enrolled subjects, etc.) due to the pandemic. Principal Investigators should review UCSF Interim Policy on Human Subjects-Related Research and contact HRPO via email at: [email protected] to notify them of the University’s policy and make appropriate arrangements. UCSF is not contacting sponsors centrally at this time. See the open letter to research sponsors and collaborating institutions.
• Recipients must adhere to all other reporting and submission requirements specified in their HRPO approval memorandum.

SOURCE: USAMRAA Supplemental Guidance March 25, 2020, HRPO FAQs, FAQs from COGR March 19, 2020

• Due to the impact of COVID-19, CDC may accept a brief statement from recipients for continuation requests scheduled to come in from April 1, 2020, to December 31, 2020, for projects with planned future support. CDC programs will post any specific instructions in their continuation guidance. CDC will use the brief statements to verify that recipients are in a position to resume or restore their project activities and accept a planned continuation award. CDC may examine the need to extend this approach on subsequent continuation award start dates as recipients have an opportunity to assess the situation.

SOURCE: Flexibilities Available to Applicants and Recipients Affected by COVID-19 and FAQs

If recipients are able to make temporary modifications of activities to accomplish project goals, a request for a change in scope must be submitted through Grant Solutions and approved by a Grants Management Officer. If the request states that the change is temporary and a result of COVID-19, the project scope will automatically revert back to the previously approved project (e.g. no request is required to return to the original scope). Recipients who are unable to conduct award activities during the public health emergency do not need to submit a request to change the scope or to rebudget. Instead, they should notify the Grants Management Specialist and Federal Project Officer listed on the Notice of Award that cessation of award activities has occurred. The request may be sent through Grant Solutions or via email. Prior approval is not required to resume project activities that had ceased. Recipients are responsible for reporting specific COVID-19 impacts that led to any cessation of project activities in their progress report for the affected period. Recipients should not assume additional funding will be available to offset the impacts of COVID-19 or to resume award activities to complete the project.  Waivers are granted until the public health emergency ends but no more than 90 days.

SOURCE: HHS Memo to Recipients of OASH Grants and Cooperative Agreements

Flexibilities are applicable to ACF applicants and recipients where the entity is conducting human service activities related to or affected by COVID-19. Affected entities are those that have been closed or that have business activities that are hindered due to COVID-19 precautionary measures and/or illnesses. Affected entities will be asked to provide documentation to the respective ACF Program Office describing the effects, including how long the program and ACF-related work or instruction were and/or will be affected.

For continuation requests scheduled from April 1, 2020 to December 31, 2020 for projects with planned future support, ACF will accept a brief statement from recipients verifying that they are inn a position to: 1) resume or restore project activities; and 2) accept a planned continuation award. ACF will post any specific instruction on their website at: https://www.acf.hhs.gov/coronavirus. ACF will examine the need to extend this approach on subsequent continuation award start dates as recipients have an opportunity to assess their situation.

ACF will allow the recipient to delay submission of any pending financial, performance, and other reports required for closeout of expired projects, provided that proper notice about the reporting delay is given to the agency. This delay may not exceed one year after the award expires.

SOURCE: Administration for Children & Family IM-ACF-OA-2020-01

Principal Investigators (PIs) should work with their OSR Staff regarding any changes that may need to be made to a study’s design and/or timeline. If it is determined that AHRQ prior approval or review is needed, formal requests should submit to the Grants Management Specialist named on the most recent NOA by your OSR C&G Officer. AHRQ does not waive the requirement for recipients to notify the agency of problems, delays, or adverse conditions related to COVID-19 on a grant-by-grant basis

SOURCE: NOT-HS-20-010

Intake, follow-up, reassessment, or discharge data (GPRA/NOMS) may be collected telephonically or electronically.

Data (GPRA/NOMS) collection targets should not be changed as a result of the public health emergency. SMHSA will review data with the lens of the current emergency situation.

Grant recipients should make every effort to safely collect data. SAMHSA understands there are challenges to collecting data during the public health emergency and will take into account the period of time in which there was an emergency, which prevented the collection of data.

If recipients are able to collect data but not in the timelines provided by SAMHSA, they should collect and submit the data to SAMHSA.

SOURCE: COVID-19 Information for SAMHSA Discretionary Grant Recipients

• As this Public Health Emergency continues, recipients may identify additional cost-related flexibilities. NIH will consider requests on a case-by-case basis. Recipients should contact assigned grants management and program officials and provide detailed justification outlining the effect of COVID-19 and flexibility required.

SOURCE: NIH FAQs, NOT-OD-20-086, OMB M-20-17